Israel-based DreaMed scored another FDA clearance, expanding the availability of its AI-supported diabetes care platform to Type 2 patients.
The Advisor Pro Al Clinical Decision Support System helps healthcare providers manage the insulin needs of patients who use insulin pumps or injections and monitor their glucose levels using a continuous glucose monitor and/or blood glucose meters.
The...
The FDA has granted Isreal-based DreaMed Diabetes a de novo request for its artificial intelligence-powered software for providers managing patients with Type 1 diabetes.
“This is an innovation that can improve people’s lives and the FDA decision confirms what we believe is an important step in making a more meaningful connection between the healthcare provider and their type 1 diabetes patients...
Israel-based DreaMed Diabetes announced this week that it has raised $3.3 million from Norma Investments, Russian businessman Roman Abramovich and one other unnamed angel.
The funds will mainly be used for further development of DreaMed’s Advisor, the company's decision support software that can be licensed and embedded into partners' diabetes management platforms.
For example, in February, the...
